High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
Efrat Luttwak, Raphaël Steiner, Paul A. Hamlin, Kevin A. David et al.
Journal
Blood
Topics
Chronic Lymphocytic Leukemia Research
article
High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease
Efrat Luttwak, Raphaël Steiner, Paul A. Hamlin, Kevin A. David, Ariela Noy, Anita J. Kumar, Paola Ghione, William Thomas Johnson, Ahmet Doǧan, Jennifer Kimberly Lue, Santosha Adipudi Vardhana, Venkatraman Seshan, Andrew M. Intlekofer, Pallawi Torka, Alexander P. Boardman, Zachary D. Epstein‐Peterson, Andrew David Zelenetz, Alfredo Rivas‐Delgado, Alison J. Moskowitz, Pallavi Galera, Philip C. Caron, Gilles Salles, Robert N. Stuver, Lorenzo Falchi, Sarah McCue Horwitz, Maria Lia Palomba, Sean E. Healton
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 144(Supplement 1)
Institutions
Memorial Sloan Kettering Cancer Center (US), Kettering University (US)
Funders
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Gilead Sciences, Celgene, Memorial Sloan-Kettering Cancer Center, TG Therapeutics, MEI Pharma, Adaptive Biotechnologies, BeiGene, CTI Biopharma, Incyte, Seagen, Kyowa Hakko Kirin, Swedish Orphan Biovitrum, MorphoSys, Ipsen, Genentech, Pharmacyclics, Loxo Oncology, Daiichi Sankyo Europe